Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China

doi:10.1007/s00262-021-02869-9

HFCAS OpenIR

	Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
	Zhang, Xiangyu 1; Zeng, Liang 1; Li, Yizhi 1; Xu, Qinqin 2; Yang, Haiyan 1; Lizaso, Analyn 3; Mao, Xinru 3; Jin, Ren'an 4; Zeng, Yu 5; Li, Qinglin 6; Wang, Jianbo 7; Li, Yang 8; Zhang, Yongchang 1,9; Yang, Nong 1,9
	2021-02-10
发表期刊	CANCER IMMUNOLOGY IMMUNOTHERAPY
ISSN	0340-7004
通讯作者	Zhang, Yongchang(zhangyongchang@csu.edu.cn) ; Yang, Nong(yangnong0217@163.cn)
摘要	Background This study evaluated the efficacy and safety of anlotinib combined with programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Patients and methods SCLC (n = 28) and NSCLC (n = 177) patients who received treatment at Hunan Cancer Hospital between June 1, 2019, and July 1, 2020, were retrospectively analyzed. Progression-free survival (PFS) and treatment responses were compared among patients who received combination therapy of anlotinib plus PD-1 inhibitor, or monotherapy of either chemotherapy or PD-1 inhibitor. Independent prognostic factors were identified by Cox regression analysis. Results Patients with relapsed SCLC who received anlotinib plus PD-1 inhibitor as a >= second-line therapy (n = 14) had a significantly longer PFS than those who received PD-1 inhibitor alone (n = 14, 5.0 vs. 3.0 months; P = 0.005). For patients with previously untreated wild-type NSCLC, the combination therapy in the first-line setting (n = 6) provided a marginally longer PFS than mono-chemotherapy (n = 6, 8.0 vs. 3.0 months; P = 0.075). For patients with relapsed NSCLC, the combination therapy in the >= second-line setting (n = 62) resulted in significantly higher objective response rate (19.3 vs. 5.0 vs. 2.4%; P = 0.013) and longer PFS (8.0 vs. 2.0 vs. 2.0 months; P <0.001) as compared to monotherapy of either chemotherapy (n = 41) or PD-1 inhibitor (n = 62). Anlotinib and PD-1 blockade combination therapy was an independent predictive factor of longer PFS (P <0.001). Conclusion The combination of anlotinib and PD-1 inhibitor has promising efficacy and manageable toxicity as a second- or later-line treatment of relapsed NSCLC and possibly for relapsed SCLC.
关键词	Anlotinib Immunotherapy Programmed death 1 inhibitor Lung cancer
DOI	10.1007/s00262-021-02869-9
收录类别	SCI
语种	英语
资助项目	Natural Science Foundation of China[81760529] ; Natural Science Foundation of Hunan Province[2018RS3106] ; Natural Science Foundation of Hunan Province[2018SK50901] ; Natural Science Foundation of Hunan Province[kq1801102] ; Natural Science Foundation of Hunan Province[2019-TJ-N04] ; Natural Science Foundation of Hunan Province[2019JJ50357] ; Natural Science Foundation of Hunan Province[2019SK4010] ; Natural Science Foundation of Hunan Province[2020JJ5340] ; Natural Science Foundation of Hunan Province[2020JJ3025]
项目资助者	Natural Science Foundation of China ; Natural Science Foundation of Hunan Province
WOS研究方向	Oncology ; Immunology
WOS类目	Oncology ; Immunology
WOS记录号	WOS:000616738100001
出版者	SPRINGER
引用统计	被引频次：38[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/119645
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Yongchang; Yang, Nong
作者单位	1.Cent South Univ, Hunan Canc Hosp, Dept Med Oncol,Xiangya Sch Med, Lung Canc & Gastrointestinal Unit,Affiliated Canc, Changsha 410013, Peoples R China 2.Qinghai Prov Peoples Hosp, Xining 810000, Peoples R China 3.Burning Rock Biotech, Guangzhou 510300, Peoples R China 4.Zhejiang Univ, Sir Run Run Shaw Hosp, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China 5.Tongji Univ, Tongji Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 7.Shandong Univ, Dept Radiotherapy, Qilu Hosp, Jinan, Shandong, Peoples R China 8.Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei, Peoples R China 9.Univ South China, Grad Sch, Hengyang 421001, Hunan, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Xiangyu,Zeng, Liang,Li, Yizhi,et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY,2021.
APA	Zhang, Xiangyu.,Zeng, Liang.,Li, Yizhi.,Xu, Qinqin.,Yang, Haiyan.,...&Yang, Nong.(2021).Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.CANCER IMMUNOLOGY IMMUNOTHERAPY.
MLA	Zhang, Xiangyu,et al."Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China".CANCER IMMUNOLOGY IMMUNOTHERAPY (2021).